While subjective, this observation aligns with the peptides known mechanisms and provides a tangible indicator that something is happening at the tissue level
Individuals with significant stubborn fat deposits, particularly visceral abdominal fat, may benefit disproportionately
Patients interested in learning more about BPC-157 therapy can review our BPC-157 Therapy Program and our Peptide Therapy Clinic
hospitalization required Maintenance of Remission: Immunomodulators (azathioprine, 6-MP, methotrexate) for steroid-dependent or frequently-relapsing disease Biologic monotherapy or combination therapy (biologic + immunomodulator) for moderate-to-severe disease Step-up or top-down approach based on disease severity, patient risk factors, and prior therapy Biologic Therapy Targets: TNF-: Infliximab (IV), adalimumab (SC), certolizumab pegol (SC) IL-12/23: Ustekinumab (IV induction, SC maintenance) Integrin: Vedolizumab (IV) IL-23: Risankizumab (IV induction, SC maintenance) JAK inhibition: Upadacitinib (oral) Surgical Management Surgery is indicated in approximately 7080% of patients with Crohns disease over their lifetime, per StatPearls
Home Peptide Dosage Calculator Calculate peptide units, mL, concentration, vial size, and reconstitution
